Shanghai Pharma Gains Approval For Asset Restructuring
This article was originally published in PharmAsia News
Shanghai Pharmaceutical recently gained full approval from regulatory authorities for a merger with Shanghai Industrial Pharmaceutical Investment and Shanghai Zhongxi Pharmaceutical
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.